OFATUMUMAB and PYREXIA

Overview

PYREXIA is the #3 most commonly reported adverse reaction for OFATUMUMAB, manufactured by Novartis Pharmaceuticals Corporation. There are 3,524 FDA adverse event reports linking OFATUMUMAB to PYREXIA. This represents approximately 4.3% of all 82,579 adverse event reports for this drug.

OFATUMUMAB has an overall safety score of 78 out of 100. Patients taking OFATUMUMAB who experience pyrexia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

PYREXIA is moderately reported among OFATUMUMAB users, representing a notable but not dominant share of adverse events.

Other Side Effects of OFATUMUMAB

In addition to pyrexia, the following adverse reactions have been reported for OFATUMUMAB:

• FATIGUE — 5,388 reports
• HEADACHE — 4,533 reports
• PAIN — 3,478 reports
• CHILLS — 3,440 reports
• INFLUENZA LIKE ILLNESS — 2,787 reports
• NAUSEA — 1,777 reports
• MULTIPLE SCLEROSIS RELAPSE — 1,614 reports
• COVID 19 — 1,505 reports
• ASTHENIA — 1,473 reports
• GAIT DISTURBANCE — 1,398 reports

Other Drugs Associated with PYREXIA

The following drugs have also been linked to pyrexia in FDA adverse event reports:

Does OFATUMUMAB cause PYREXIA?

PYREXIA has been reported as an adverse event in 3,524 FDA reports for OFATUMUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is PYREXIA with OFATUMUMAB?

PYREXIA accounts for approximately 4.3% of all adverse event reports for OFATUMUMAB, making it one of the most commonly reported side effect.

What should I do if I experience PYREXIA while taking OFATUMUMAB?

If you experience pyrexia while taking OFATUMUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages